sorafenib has been researched along with cholestyramine resin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (cholestyramine resin) | Trials (cholestyramine resin) | Recent Studies (post-2010) (cholestyramine resin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 2,669 | 342 | 190 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, R; Agatsuma, T; Bange, J; Bartz, R; Chapman, RW; Fukuchi, K; Gruner, K; Hanai, M; Hanzawa, H; Häussinger, D; Hayashi, S; Imai, E; Kashimoto, Y; Kawaida, R; Komori, H; Lange, T; Martinez, A; Mayer, JA; Oda, Y; Ohtsuka, T; Redondo-Müller, M; Saito, S; Takahashi, M; Watanabe, I; Wirtz, P | 1 |
1 other study(ies) available for sorafenib and cholestyramine resin
| Article | Year |
|---|---|
Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Line, Tumor; Cholestyramine Resin; Female; Gene Expression Regulation; Humans; Ileum; Liver; Mice; Mice, Inbred BALB C; NIH 3T3 Cells; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Sorafenib | 2019 |